Solara Active Pharma Sciences Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/5t548gdavee2cdo85vur9q5j.pdf

Key Takeaways


The Called-Off Merger & Leadership Reset

Arun Kumar: "Unfortunately, with an over dependence on COVID products in the case of Aurore and in the recent six months we have seen a lack of demand for the primary tactical products that Aurore was selling, dropping significantly where the economies does not make any more sense for the Solara shareholders to keep the ratios intact, and it would not be appropriate for us to then recommend to the Board that as promoters that the merger should go through."

The Idle Vizag Plant


R&D Pipeline Failure & New Product Strategy

Arun Kumar: "This was the first time in the history of Solara that in the last 12 months, we were not successful on that front. So that is why the revenue from that activity has been shown as zero while the costs have been incurred."

Regulatory Overhang: Cuddalore OAI Status


Margin & Balance Sheet Pressure

Jitesh Devendra: "Our focus right now is to strengthen the foundation of Solara to get back to its historical run rates... the next focus is in terms of how we improve our EBITDA margins, our gross margins which has been traditionally at about 50% to 54%, we see that coming back in second half of this year."

Ibuprofen & Non-Ibu Business Dynamics


CRAMS & Long-Term Vision

Arun Kumar: "I do not think the vision has moved maybe the timing has shifted... I am very, very confident that we will still emerge amongst the top 10 global players. We probably will take two more years but and that is to do with the circumstances in the business environment that we operate in."

Guidance & Commitments

CommitmentSpecificsTimeline
OAI reclassificationCuddalore OAI status reclassified based on data provided to US FDAH1 FY23
New product filingsFile at least six new productsFY23
Vizag inspectionVizag site inspected by regulatorsFY23
Gross margin recoveryGross margins return to 50–54% rangeH2 FY23
Raw material cost normalizationRaw material prices normalize as international situation stabilizesQ2 FY23
Two-product margin pressurePrice reversion and RM price increase on two key products normalizeH2 FY23
COVID inventory liquidationTwo COVID products in inventory sold down with no loss expectedQ1–Q2 FY23
Arun Kumar Aurore exitFull exit from Aurore interest, full commitment to Solara3–6 months
Organic capex₹100 Cr for ongoing Vizag investments and maintenance capexFY23
R&D spend capR&D spend rationalized to not more than ₹54–55 Cr run rateOngoing

Key Metrics

MetricQ4 FY22
Revenue₹367 cr, 90% of historical run rate
FY2022 revenue₹1,289 cr, compared to ₹1,645 cr in FY2021
Gross margin44.1% in Q4; 47.6% for FY2022, compared to 54.7% in FY2021
Adjusted EBITDA₹50 cr, 13.6% margin
FY2022 consolidated EBITDA₹92 cr, compared to ₹400 cr in FY2021
Reported EBITDA margin (adjusted for inventory changes and Vizag)19.7%
Core business revenue₹367 cr in Q4; ₹1,288 cr for FY2022
Core business EBITDA₹40 cr in Q4; ₹200 cr for FY2022
R&D led growth business revenueZero in Q4 and FY2022
R&D led growth business EBITDAminus ₹54 cr for FY2022
Vizag led business revenueZero in Q4 and FY2022
Vizag led business EBITDAminus ₹58 cr for FY2022
Net debt increaseOver 50%
Credit ratingA- for long-term and working capital, retained
CRAMS revenue share7% to 8% of total revenues
Ibuprofen price$11 to $12 per kilo average
New products revenue share5% of revenue, from products launched in prior year
FY2023 planned organic capex₹100 cr, including Vizag investments and maintenance capex
Ibuprofen annual demand sold in FY202240%
FY2023 new product filing targetAt least six new products
Raw material cost increase30% to 40% for key materials; solvents up more than 40%
Historical gross margin range50% to 54%